ATS Corporation

The business

ATS Corporation designs and builds sophisticated automated manufacturing and assembly systems — the robotic production lines and machines that customers use to make everything from medical devices and drug-delivery products to electric-vehicle batteries and consumer goods. It sells turnkey automation solutions plus a growing base of after-sales services, spare parts and digital software, and it operates globally across life sciences, transportation, food and consumer markets.

Life sciences (medical devices and pharma automation) has been a particularly attractive end-market given regulatory complexity and long product cycles. ATS grows both organically and through a steady program of acquisitions that add capabilities and geographic reach. Trailing revenue is close to $3 billion, and the company carries a substantial order backlog that provides revenue visibility.

The moat

Deep engineering expertise in complex, regulated automation (especially life sciences) that few competitors can match end-to-end.

Large installed base generating recurring after-sales service, parts and software revenue.

Sizeable order backlog and long customer relationships that provide visibility and switching costs.

Financial snapshot

Most recent reported period : Q4 FY2026 (fiscal year ended March 31, 2026). Figures reflect the review date — confirm current numbers before acting.

Free cash flow yield & sustainable growth

Free cash flow yield : ≈4.5% (est.)forward P/E ~21x (trailing depressed by one-off costs); low-single-digit FCF yield on recovering earnings

Revenue has grown strongly, up in the mid-teens on a trailing basis, driven by organic growth in life sciences and acquisitions, though margins and net income have been pressured by integration costs and weaker transportation/EV demand. The backlog underpins continued top-line growth, and management targets margin expansion and improved free cash flow as the order book converts.

The investment case is that ATS converts its growing revenue and backlog into materially higher earnings and free cash flow as one-time costs roll off and mix shifts toward higher-margin life sciences and services.

See the full free-cash-flow yield ranking →

Valuation & what to watch

The trailing P/E is elevated because reported earnings have been depressed by acquisition costs, restructuring and end-market softness in areas like EV and transportation, so the forward multiple in the low-20s is a better gauge. On that basis ATS trades at a premium-industrial valuation that reflects its high-value automation niche and backlog.

The stock is priced for a recovery in margins and earnings; the gap between the high trailing multiple and the much lower forward multiple captures the market's expectation that profitability normalizes as revenue grows and one-off costs fade.

Dividend

Pays no dividend; capital is directed to growth and acquisitions.

Risks & the bear case

• Trailing earnings are thin relative to the share price, so the stock depends on a margin and earnings recovery.
• Exposure to cyclical end-markets like EV/transportation, which have softened.
• Acquisition-driven growth carries integration and execution risk.
• Large custom-automation projects can face timing, cost-overrun and lumpiness risks.

Recent developments

As of 2026-08-05, this profile reflects ATS Corporation's Q4 FY2026 (fiscal year ended March 31, 2026); consult the company's latest filings and the linked sources for any developments since.

Verdict

A high-quality automation franchise with strong life-sciences exposure and a solid backlog, but currently earning below its potential and priced on a recovery. Attractive for investors who trust the margin-normalization thesis; the rich trailing multiple and cyclical pockets warrant moderate conviction.